Topricin
NDC 61500-5547, aesculus hippocastanum, arnica montana, belladonna, calendula officinalis, crotalus horridus, echinacea, graphites, heloderma horridum, lachesis mutus, naja tripudians, phosphorus, rhus toxicodendron, ruta graveolens, sulfur, cream, from Topical BioMedics, Inc..
- Product NDC
- 61500-5547
- Status
- Listed
- Labeler
- Topical BioMedics, Inc.
- Dosage form
- CREAM
- Route
- TOPICAL
- Product type
- HUMAN OTC DRUG
- Marketing category
- UNAPPROVED HOMEOPATHIC
- Application
- —
- DEA schedule
- None
curl https://api.healthcare.dev/v1/drugs/ndc/61500-5547 \ -H "Authorization: Bearer $HDEV_API_KEY"
Product
Active ingredients and packages
Active ingredients
- PHOSPHORUS9 [hp_X]/227g
- ARNICA MONTANA6 [hp_X]/227g
- CROTALUS HORRIDUS HORRIDUS VENOM8 [hp_X]/227g
- ECHINACEA ANGUSTIFOLIA4 [hp_X]/227g
- GRAPHITE6 [hp_X]/227g
- HELODERMA HORRIDUM VENOM8 [hp_X]/227g
- LACHESIS MUTA VENOM8 [hp_X]/227g
- NAJA NAJA VENOM8 [hp_X]/227g
- RUTA GRAVEOLENS FLOWERING TOP6 [hp_X]/227g
- AESCULUS HIPPOCASTANUM FLOWER6 [hp_X]/227g
- ATROPA BELLADONNA6 [hp_X]/227g
- TOXICODENDRON PUBESCENS LEAF8 [hp_X]/227g
- CALENDULA OFFICINALIS FLOWERING TOP4 [hp_X]/227g
- SULFUR8 [hp_X]/227g
| Package NDC | NDC-11 | Package |
|---|---|---|
| 61500-5547-0 | 61500554700 | 2 g in 1 PACKET (61500-5547-0) |
| 61500-5547-1 | 61500554701 | 21 g in 1 TUBE (61500-5547-1) |
| 61500-5547-2 | 61500554702 | 57 g in 1 TUBE (61500-5547-2) |
| 61500-5547-4 | 61500554704 | 113 g in 1 JAR (61500-5547-4) |
| 61500-5547-8 | 61500554708 | 454 g in 1 BOTTLE (61500-5547-8) |
| 61500-5547-9 | 61500554709 | 227 g in 1 BOTTLE (61500-5547-9) |
Linked data
RxNorm, label and prices
RxNorm concepts
RxNorm links no concept to this product's packages.
Related lookups
No FDA label, Medicare Part B payment limit or NADAC price is linked to this product.
Use it
Look up 61500-5547 from code or an agent
curl https://api.healthcare.dev/v1/drugs/ndc/61500-5547 \ -H "Authorization: Bearer $HDEV_API_KEY"
Using the healthcare.dev MCP server, look up NDC 61500-5547. Tell me the product, its labeler, dosage form and route, its packages, and the RxNorm concepts it maps to.
Source: FDA, release 2026-10-23. Public domain. Reference data, not medical advice.